AIP
CTXR icon

Almanack Investment Partners’s Citius Pharmaceuticals CTXR Stock Holding History

Almanack Investment Partners’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-36
Closed -$1K – 392
2022
Q3 		$1K Buy
+36
New +$989 ﹤0.01% 787

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Almanack Investment Partners's CTXR Position: Q4 2022 in Review

Almanack Investment Partners sold out of Citius Pharmaceuticals (CTXR) in Q4 2022, closing a stake of 36 shares — an estimated $1K sold.

Almanack Investment Partners first reported a position in CTXR in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 54 funds tracked by Wall St. Rank hold CTXR as of Q4 2022.

  • Almanack Investment Partners reported no remaining Citius Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 36 Citius Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Almanack Investment Partners first reported a position in Citius Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Citius Pharmaceuticals position peaked at $1K in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.